Published On:October 17 2023
Story Viewed 918 Times
"Granules and NIPER Collaborate to Establish Cutting-Edge Centre of Excellence"
Granules India, a leading pharmaceutical company, has signed a Memorandum of Understanding (MoU) with the National Institute of Pharmaceutical Education and Research (NIPER) located in Mohali, Chandigarh, to establish the Chigurupati Centre of Excellence in Innovative and Sustainable Pharmaceutical Development (CCE-ISPD).
Krishna Prasad Chigurupati, the Chairman and Managing Director of Granules India, expressed their dedication to pushing the boundaries of pharmaceutical innovation. He stated, "At Granules India, we are committed to pushing the boundaries of pharmaceutical innovation, and through this partnership with NIPER, we aim not just to make life-saving medicines, but to make a difference."
He went on to emphasize the importance of the CCE-ISPD, saying, "The CCE-ISPD is a testament to our dedication to sustainable pharmaceutical development, and we are enthusiastic about the transformative impact it will have on industry and society."
Dulal Panda, Director of NIPER, shared his excitement about the collaboration, stating, "The CCE-ISPD will be a nurturing ground for innovative ideas and sustainable solutions, shaping the future of pharmaceuticals. We are honored to work alongside Granules India, and together, we will redefine the landscape of sustainable pharmaceutical research and development."
The CCE-ISPD will concentrate on various critical areas, including the exploration of plant-based excipients, advancements in polymer-free pharmaceutical formulations, and the development of resource-efficient and energy-efficient pharmaceutical products, among other research initiatives.
Granules India has committed its support for establishing and maintaining the research center. This partnership includes the creation of state-of-the-art laboratories and research facilities within the NIPER campus. This collaboration promises to be a significant step forward in the pursuit of innovative and sustainable pharmaceutical solutions.
HBL